AU2900100A - Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss - Google Patents

Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss

Info

Publication number
AU2900100A
AU2900100A AU29001/00A AU2900100A AU2900100A AU 2900100 A AU2900100 A AU 2900100A AU 29001/00 A AU29001/00 A AU 29001/00A AU 2900100 A AU2900100 A AU 2900100A AU 2900100 A AU2900100 A AU 2900100A
Authority
AU
Australia
Prior art keywords
activity
treatment
methods
bone loss
diseases related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29001/00A
Inventor
Marc Ouellet
M. David Percival
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Publication of AU2900100A publication Critical patent/AU2900100A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU29001/00A 1999-03-05 2000-03-02 Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss Abandoned AU2900100A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12299699P 1999-03-05 1999-03-05
US60122996 1999-03-05
PCT/CA2000/000226 WO2000051597A1 (en) 1999-03-05 2000-03-02 Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss

Publications (1)

Publication Number Publication Date
AU2900100A true AU2900100A (en) 2000-09-21

Family

ID=22406125

Family Applications (1)

Application Number Title Priority Date Filing Date
AU29001/00A Abandoned AU2900100A (en) 1999-03-05 2000-03-02 Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss

Country Status (2)

Country Link
AU (1) AU2900100A (en)
WO (1) WO2000051597A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
JP2003531179A (en) 2000-04-26 2003-10-21 クイーンズ ユニバーシティ アット キングストン Formulations and methods of using nitric oxide mimetics for malignant cell phenotype
DE10054278A1 (en) * 2000-11-02 2002-05-08 Bayer Ag Use of soluble guanylate cyclase stimulators for the treatment of osteoporosis
US20040235728A1 (en) * 2001-11-08 2004-11-25 Stoch Selwyn Aubrey Compositions and methods for treating osteoporosis
EP1539185A4 (en) * 2002-05-02 2006-04-05 Osteoscreen Inc Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates (no-bisphosphonate)
WO2005046660A1 (en) * 2003-11-13 2005-05-26 Cell Center Cologne Gmbh MODULATING SUBSTANCES OF THE NITRIC OXID (NO) - CYCLIC GUANOSINE - 3’,5’- MONOPHOSPHATE (cGMP) SIGNALING PATHWAY FOR THE TREATMENT OF DENTAL DISORDERS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059264B1 (en) * 1992-11-05 1995-06-16 Berrazueta Fernandez Jose Ramo USE OF NITROVASODILATATORS IN THE PREPARATION OF ANTI-INFLAMMATORY AND ANALGESIC MEDICINES FOR TOPICAL USE.
US5898038A (en) * 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors

Also Published As

Publication number Publication date
WO2000051597A1 (en) 2000-09-08

Similar Documents

Publication Publication Date Title
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
IL196301A0 (en) Medicament for the treatment of hapatitis c
GB0015745D0 (en) Treatment of bone diseases
AU7870900A (en) Treatment of scar tissue using lipoic acid
AUPQ877300A0 (en) Topical treatment of skin
AU2000274383A1 (en) Preparation for treating diseases of bone tissues
HUP0104963A3 (en) Compositions for the treatment of skin diseases
AU2001236713A1 (en) Methods for treatment of lysosomal storage diseases
AU3896900A (en) Treatment of pain
AUPQ474599A0 (en) Endoscope for surgical treatment of haemorrhoids
AU7106300A (en) Treatment of skin disorders
AU2900100A (en) Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss
AU1878201A (en) Composition for the treatment of damaged tissue
NZ513686A (en) Treatment of trauma
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
GB2360453B (en) Treatment of skin conditions
AU9545701A (en) Use of carp inhibitors for the treatment of heart diseases
AU1405001A (en) Treatment of diseases
AU1022501A (en) Use of compositions for the caring treatment of the skin
AU2509801A (en) Method for the cosmetic treatment of human skin
AU3501100A (en) Synergistic combination for treatment of viral-mediated diseases
AU2683500A (en) Compositions for the treatment of pain
AU2001273801A1 (en) Dehydrobaimuxinol derivatives use as medicaments for treating or preventing regressive diseases of brain
GB0100092D0 (en) Treatment of degenerative diseases
AU7455300A (en) The band combined medical treatment of ion

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase